Véronique PERRIER
Born in France, 16 january 1969, married, 2 children
Senior Scientist at the french National Center of Scientific Research (CNRS)

University of Montpellier
Laboratory Inserm U1198,CC105, Bat24
34095 Montpellier Cedex 5, FRANCE

Tel: 00 33 467 144 830
Fax: 00 33 467 143 386
veronique.perrier@univ-montp2.fr

EDUCATION AND DEGREES

9 July 2009 **HDR** (Habilitation to Drive Research) « Therapeutic approaches for prion diseases ». Ecole Pratique des Hautes Etudes, Paris, Sorbonne. Obtained with honors and jury's congratulations.

1993-Feb1997 **Ph.D. in Biochemistry**. Doctoral program: « Structure, Fonction and Protein Engineering » University of Paris XI, Orsay, France. Obtained with honors and jury's congratulations.

PROFESSIONAL EXPERIENCE

01/2015- **Senior Scientist** in the laboratory Inserm U1198 laboratory, Team 2 « Neuroprotection and Risk factors » directed by Tangui Maurice.
Subject : Risk factors in neurodegenerative diseases.

2011-2014 **Co-Direction of Team 3** in the laboratory Inserm U710, Montpellier.
Subject : Diagnosis and Therapeutics of prion diseases.

2005-2010 **Senior scientist** (CR1) in the laboratory of Dr. Jean-Michel VERDIER, Inserm U710, University of Montpellier, Montpellier, France.
Subject : Diagnosis and Therapeutics of prion diseases.

2001-2004 **Junior scientist** (CR2) in the laboratory of Dr. Sylvain LEHMANN, CNRS, Institute of Human Genetics, Montpellier, France.
Subject : Therapeutics of prion diseases.

1997-2000 **Post-doctoral training** in the laboratory of Dr. Stanley B. PRUSINER (*Nobel Price of Medicine in 1997*), University of California San Francisco (UCSF), USA. Subject : Inhibition of prion replication by dominant negative polymorphisms

1993-1997 **Doctoral training** in the laboratory of Dr. Octavian BARZU, Pasteur Institute, Paris, France.
Subject : The metals, new structural elements in bacterial adenylate kinases

AWARD & FINANCIAL SUPPORT

Awards

2009 **Lauréat of program Chercheur d'Avenir 2009** from the Région Languedoc-Roussillon : « Potential of thienyl pyrimidine compounds in the diagnosis of prion diseases » (60 K€, 48 mois, 2010-2013).

2008 **Biotherapy Prize from Thermofisher Scientific 2008** for « Gene therapy on prion diseases » 10 K€.

Grants

2013-2015 **Scientific collaboration contract with French National Blood Transfusion Organism (EFS):** « DePriPlast » support from EFS (global 380 K€, 24 months).

2012-2014 **Principal investigator of the project :** « PrPBloodTrap » support from Alliance Biosecure Foundation (55 K€, 18 months).

2011-2012 **Principal investigator of the project :** « PrPdetection » support from Alliance Biosecure Foundation (50 K€, 18 months).

2010 **Participant to the project:** « PrionTrap » support from Alliance Biosecure Foundation, coordinator Dr. Joan Torrent (40 K€- 12 months).

2007-2009 **Principal investigator of the project :** « PrPdetection » from the National Research Agency (ANR EMP 2007-100 K€- 24 months).

2004 **Carrefour Foundation fellowship** obtained to support Dr. C. Crozet (12 months).

2001-2003 **Principal investigator on the project** « Gene and cell therapy of prion diseases ». supported from the French Ministry of Research (GIS prions 196 K€- 24 months).

Exchange programm

2014-2016 **PHC Cai YuanPei,** support from French Ministry of Foreign Affairs, Campus France.

PATENTS

2008 *«* Method useful for amplifying, detecting and depleting pathologic forms of the cellular prion protein ». Perrier V. ; Robitzer M., Verdier J.-M. PCT/IB2008/055465 date : 19/12/2008.

2006 *«* Method for detecting encephalopathies ». Perrier V. ; Grégoire C., Verdier J.-M. Brevet International n° WO/2006/131676 date : 14/12/2006.

TRAINING of STUDENTS & POST-DOCS

Ph.D. students

2015-2018 **Direction of the thesis of Mr Pierre-André Lafon,** Inserm U1198 (Contract from the French Ministery of Research, 36 months.

2015-2017 **Co-Direction of the thesis of Miss Wang Yunyun,** Inserm U1198 (Contract from the Chinese Scholarship Council via PHC Cai Yuan Pei, 24 months).

2009-2012 **Direction of the thesis of Mr Thibaut Imberdis,** Inserm U710 (Contract from the French Ministery of Research, 36 months + 12 months fellowship from Alliance Biosecure Foundation). Defence of thesis : 7 December 2012. Currently in Dr. David Harris Lab, Boston University, USA.

2006-2009 **Co-direction of the thesis of Miss Adeline Ayrolles,** with Dr. Verdier. Inserm U710 (**Contract from Inserm and Région Languedoc Roussillon**, 36 months). Defence of thesis : 27 November 2009. Currently, ingineer contract at Institute of Cancerology IRCM, Montpellier.

2006-2009 **Co-direction of the thesis of Miss Karine Toupet,** with Dr. Verdier Inserm U710 (**Doctoral fellowship from the french Ministery of Research**, 36 months). Defence of thesis : 30 October 2009. Ingineer contract at Institute of Neurosciences INM, Montpellier

2005-2009 **Participation to the thesis of Mr Driss El Moustaïne** with Dr. Joan Torrent. Inserm U710. Defence of thesis: 23rd June 2009. Post-doctoral training at Institute of

functional genomic IGF, Montpellier, with Dr. Philippe Rondard.

2001-2003 **Participation to the thesis of Mr. Jérôme Solassol, (M.D.)** with Dr. Lehmann. Institute of Human Genetic, IGH, Montpellier. Defence of thesis : 11th December 2003. Currently, MCU-PH St-Eloit Hospital, Montpellier.

Master students

2016 - **Co-supervisor of Miss Han Zhao, M2R BioMed « Cancer biology »,** University of Montpellier. Training at IRCM, Montpellier, (5 months-Feb-June 2016).

2015 - **Supervisor of Miss Marina Cefis, M1R BioMed,** University of Montpellier. Training at Inserm U1198, Montpellier, (5 months-Feb-June).

- **Co-supervisor of Miss Hajar Harmachi, M2R BioMed,** University of Montpellier. Training at Inserm U1198 and IRCM, Montpellier, (5 months-Feb-June).

2014 **- Supervisor of Mr Pierre-André Laffon, M2R BioMed,** University of Montpellier 2. Training at Inserm U710, UM2, Montpellier, (6 months-Jan-July).

- Co-Supervisor of Miss Hajar Harmachi, M1R BioMed, University of Montpellier 2. Training at Inserm U710 and CRBM, Montpellier, (6 months-Feb-August).

2012-2013 **Supervisor of Miss Anne Keneghan, M2R EPHE,** University of Paris Sorbonne. Training at Inserm U710, UM2, Montpellier, (12 months- Sept-June).

2011-2012 **Supervisor of Miss Alexia Séraidaris, M1 BIOTIN,** University of Montpellier 2. Training at Inserm U710, UM2, Montpellier, (6 months- Nov-April).

2009 **Supervisor of Mr Imberdis Thibaut, M2Pro Biotechnologies**, University of Montpellier 2. Training at Inserm U710, UM2, Montpellier, (9 months- Jan-Sept).

2005-2006 **Supervisor of Miss Karine Toupet, M2R Bio-Santé,** University of Montpellier 2. Training at Inserm U710, UM2, Montpellier, (9 months-Nov-June).

2004-2005 **Supervisor of Mr. Alain Corinus**, **ingineer in Diploma from Ecole Pratique des Hautes Etudes EPHE**. Training at Inserm U710, UM2, Montpellier, (18 months-2004-05). Defence of degree : October 2005.

2003 **Supervisor of Miss Claire Mariani, M2R Bio-Santé** University of Montpellier 2. Training at Institute of human Genetics, Montpellier, (6 months-Jan-Jun).

Post-doc

2006-2007 **Supervisor of Mr Guillaume Poncet, ATER** grant from **Ecole Pratique des Hautes Etudes**. Training at Inserm U710, UM2, Montpellier (12 months). Then, did a Post-doctoral training in the laboratory of Dr. Prusiner, University of california San Francisco, USA. Position in a Biotech compagny, Swizerland.

2005-2006 **Supervisor of Dr. Catherine Grégoire, ATER** grant from **Ecole Pratique des Hautes Etudes.** Training at Inserm U710, UM2, Montpellier, (12 months).

2002-2004 **Supervisor (100%) of Miss Carole Crozet**, post-doctoral fellow at the Institute of Human Genetics, UPR1142, CNRS (36 months). Currently Inserm researcher since 2005, at Institute of Biotherapies IRB, Montpellier.

TEACHING

2015	- **Co-supervisors of UE3 « Physio-pathology » (30h) Master2 BioSanté-Neurosciences**: C. Rivat, V. Perrier. Y. Dauvilliers.
	-**Course University of Montpellier, Master2 BioSanté-Neurosciences.** « Prions and prion-like mechanism of propagation».
2011, 2014	**Member of the jury in the Master2 BioSanté-Neurosciences**
2013-2016	**Course University of Montpellier, Master2 BioSanté -Immunology.** « Prions and immunity».
2006-2010	**Course University of Nîmes, Master2 Bio-engineering.** « The prion protein: Diagnostic and therapeutic applications».
2005, 2007	**Course Master2 EPHE, Human Virology.** « Prions and madness ».
2004, 2005	**Course Faculty of Medicine of Marseille, Master2 Transmissible diseases and Tropical pathologies.** « Jump of species barrier and emergence: The prion example».
2003	**Course University of Bordeaux, Master2 Genetic.** « Animal models and transgenesis to study prion diseases»...
1994-1995	**Course of General Microbiology 1994-1995 Pasteur Institute** ("Biochemistry of adenyl cyclase of *Bacillus anthracis*").

RESEARCH TRAVEL STAYS

- **Cai YuanPei exchange program (Campus France). Collaboration with Pr. Jianfeng Liu,** College of Life Sciences and Technology, Huazhong University of Science and technology, Wuhan, China. Two stays: 17th-25th April 2015 and 29th June-17th July.

- **Cai YuanPei exchange program supported by the French Ministry of Foreign Affairs (Campus France). Collaboration with Pr. Jianfeng Liu,** College of Life Sciences and Technology, Huazhong University of Science and technology, Wuhan, China, 10th-25th October 2014.
Invited speaker at the 2nd Sino-French School of Oncology, 14-17 October 2014.

- **Invited scientist in the laboratory of Pr. Jianfeng Liu,** College of Life Sciences and Technology, Huazhong University of Science and technology, Wuhan, China, 27th June-5th August 2014.

- **Scientific guest of the French Ministry of Foreign Affairs.** Opening ceremony of the Sino-French BioPole, BioLake Campus, Wuhan (supported by French consulate and Hubei province).
Invited speaker at the 2012 Sino-French meeting on Biological Sciences, 17-18 April 2012.

- **Visiting scientist,** University of Science and technology, laboratory of Pr. Jianfeng Liu, Wuhan, China, 10-18 Avril 2009.

- **Protein purification training** in the laboratory of Pr. Ilia Baskakov, Medical Biotechnology Center, University of Maryland, Baltimore 3-12 Février 2008. Supported by program ANR "PrPdetection".

DIVERSE

- **Expert at the Committee on Transmissible Spongiform Encephalopathie Diseases at AFSSA (French National Agency for Food and Health Safety)** Nominated by the french Minister of Agriculture 2006-2009.

- **Member (2008) and President of the scientific board (2011)** of the A3 level Animal Facility of the Montpellier University, BioCampus platform, Montpellier. (http://www.a3l3web.univ-montp2.fr/).

- **Scientific director of the laboratory L3-Prions** of the Institute of Human Geneticis (IGH), Montpellier, (2003-2004)

- **Animal Experimentation agreement** n° B34.213 renewed the 04/11/2010. Animal Experimentation training, Level 1 (11-22/03/02, Marseille, France).

****

LIST of PUBLICATIONS

1. Publications in international journals with peer-reviewing

27- Imberdis T., Ayrolles-Torro A., Duarte-Rodrigues A.,Torrent J., Alvarez-Martinez M.T., Kovacs G. G. K., Verdier J.-M., Robitzer M. & **Perrier V**. (2015) A fluorescent oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases. *In revision in Molecular Neurodegeneration.*

26- Duarte-Rodrigues A., Imberdis T., **Perrier, V** and Robitzer M. (2015) Improved synthesis of a quaterthiophene-triazine-diamine derivative, a promising molecule to study pathogenic prion proteins. *Tetrahedron Letters* (56): 368-373.

25- Huc-Brandt S, Hieu N, Imberdis T, Cubedo N, Silhol M, Leighton PL, Domaschke T, Allison WT, **Perrier V**, & Rossel M. (2014) Zebrafish prion protein PrP2 controls collective migration process during lateral line sensory system development. *PLoS One*. 9(12):e113331.

24- Acquatella Tran Van Ba I., Imberdis T. & **Perrier V**. (2013) Prion diseases and prion-like mechanism of propagation for neurodegenerative diseases. *Int. Journal of Cell Biol.* (*2013), ID 975832.*

23- Imberdis T., Ayrolles-Torro A.,Verdier J.-M. & **Perrier V**. (2013) Thienyl pyrimidine derivatives with PrP^{Sc} oligomer-inducing activity are a promising tool to study prions. *Curr. Top. Med. Chem* 13(19):2477-83.

22- Desrumaux, C., Pisoni, A., Meunier, J., Deckert, V., Athias, A., **Perrier, V.,** Villard, V., Lagrost, L., Verdier J.-M. & Maurice, T. (2013) Increased amyloid beta peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice. *Neuropsychopharmacology*, 38(5):817–25.

21- Ayrolles-Torro A., Imberdis T., Torrent J., Toupet K., Baskakov I., Poncet-Montange G., Grégoire C., Roquet-Banères F., Lehmann S., Rognan D., Pugnière M., Verdier J.-M. & **Perrier V**. (2011) Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity. *J. Neurosci.* 31(42):14882–14892.
Voir: Highlight *sur Alzheimer Research Forum* : Think oligomers are bad? Think again….

20- El Moustaine D, **Perrier V**, Acquatella-Tran Van Ba I, Meersman F, Ostapchenko VG, Baskakov IV, Lange R &Torrent J. (2011) Amyloid features and neuronal toxicity of mature prion fibrils are highly sensitive to high pressure. *J. Biol. Chem.* 286(15):13448-59.

19- Toupet K., Compan V., Crozet C, Mourton-Gilles C, Mestre-Francés N, Ibos F, Corbeau P, Verdier J.-M. & **Perrier V**. (2008). Effective gene therapy in a mouse model of prion diseases. *PloS ONE*, 3(7), e2773.

18- El Moustaine, D., **Perrier, V**., Smeller, L., Lange, R & Torrent, J. (2008) Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways. *FEBS Journal* **275**, 2021-2031.

17- Lee C.I., Yang Q., **Perrier V.** & Baskakov I.V. (2007). The dominant-negative effect of the Q218K variant of the prion protein does not require protein X. *Protein Sci.* 16(10):2166-73.

16- Solassol J., Pastore M., Crozet C., **Perrier V.** & Lehmann S. (2006). A novel copper-hydrogen peroxide formulation for prion decontamination. *J Infect. Dis.* 194(6):865-9.

15- Crozet C., Lin Y.-L., Mettling C., Corbeau P., Lehmann S. & **Perrier V.** (2004). Inhibition of PrP^{Sc} replication by lentiviral gene transfer of dominant negative PrP variants. *J. Cell Science*, 117, 5591-5597.

Voir: *Nature* (2004) Research Highlights, 432, 33. Gene therapy for prion diseases ?

14- **Perrier V.**, Solassol S., Crozet C., Frobert Y., Mourton-Gilles C., Grassi J. & Lehmann S. (2004). Anti-PrP antibodies block PrP^{Sc} replication in prion infected cell cultures by accelerating PrP^{C} degradation. *J. Neurochem.* 89, 454-463

13- Solassol J., Crozet C., **Perrier V.**, Leclaire J., Béranger F., Caminade A.-M., Meunier B., Dormont D., Majoral J.-P. & Lehmann S. (2004). Cationic phosphorous-containing dendrimers inhibit prion replication in both cell cultures and mice infected with scrapie. *J. Gen. Virol*.,85, 1791-1799.

12- **Perrier V.** (2003) Des souris traitées avec des anticorps monoclonaux anti-PrP résistent aux prions. *Médecine Science* 19(11), 1075.

11- **Perrier V.**, Crozet C., Solassol J. & Lehmann S. (2003). From chemical drug to immunotherapy: New approaches for the treatment of prion diseases. *Curr. Med. Chem.,* 3, 199-205.

10- **Perrier V.**, Kaneko K., Safar J., Vergara J., Tremblay P., DeArmond S.J., Cohen F.E., Prusiner S.B. & Wallace A. (2002). Dominant negative inhibition in transgenic mice. *Proc. Natl. Acad. Sc. USA* 99(20):13079-84.

9- **Perrier V.**, Wallace A.C., Kaneko K., Safar J., Prusiner S.B & Cohen F.E. (2000). Mimicking dominant negative inhibition of prion replication through structure-based drug design. *Proc. Natl. Acad. Sc. USA* 97(11), 6073-6078.

- *Publications from Ph.D. studies :*

8- Burlacu S., **Perrier V**., Gilles A.-M., Mispelter Joel., Barzu O. & Craescu C.T. (1999) ^{1}H, ^{13}C and ^{15}N backbone resonance assignment of *Escherichia coli* adenylate kinase, a 23.6 kDa protein. *J. Bio. NMR.* 13, 93-94.

7- **Perrier V.**, Burlacu S., Bourgeois S., Surewicz W.K. & Gilles A.M. (1998). Genetically engineered zinc-chelating adenylate kinase from *Escherichia coli* with enhanced thermal stability. *J. Biol. Chem.* 273, 19097-19101.

6- Burlacu S., **Perrier V.**, Gilles A.M., Pistotnik E. & Craescu C.T. (1998). Structural and energetic factors of the increased thermal stability in a genetically engineered *Escherichia coli* adenylate kinase. *J. Biol. Chem.* 273, 19102-19107.

5- **Perrier V.**, Burlacu S., Boussac A., Meier A. & Gilles A.M. (1998). Metal chelating properties of adenylate kinase from *Paracoccus denitrificans. Protein Eng.* 11, 917-923.

4- Briand G., **Perrier V.**, Kaouash M., Takahashi M., Gilles A.M. & Bârzu O. (1997). Characterization of Metal and Nucleotide Liganded Forms of Adenylate Kinase by Electrospray Ionisation Mass Spectrometry. *Arch. Biochem. Biophys.* 339, 291-297.

3- Deligiannakis Y., Boussac A., Bottin H., **Perrier V.**, Bârzu O. & Gilles A.M. (1997). A new non heme iron environment in *Paracoccus denitrificans* adenylate kinase studied by EPR and ESEEM. *Biochemistry* 36, 9446-9452.

2- **Perrier V.**, Surewicz W.K., Glaser P., Martineau L., Craescu C.T., Fabian H., Mantsch H.H., Bârzu O. & Gilles

A.M. (1994). Zinc chelation and structural stability of adenylate kinase from *Bacillus subtilis*. *Biochemistry* 33, 9960-9967.

1- Gilles A.M., Glaser P., **Perrier V.,** Meier A., Longin R., Sebald M., Maignan L., Pistotnik E. & Bârzu O. (1994). Zinc, a structural component of adenylate kinases from Gram-positive bacteria. *J. Bacteriol.* 176, 520-523.

2. Books , chapters

- Perrier V. (2013) The dominant negative inhibition: From molecular mechanisms to therapy. In "Prion research of Stan Prusiner and his colleagues", G. Legname and D. Riesner (eds), pp183-192, 2013, Düsseldorf university press, ISBN: 978-3-943460-43-8, Düsseldorf.

- Perrier V., Imberdis T., Ayrolles-Torro A. (2012) Anti-prion strategies for *in vivo* gene therapy assays. In *"*Prions and prion diseases: New developments*",* J.M. Verdier (eds), pp.177-187*,* 2012 Nova Sciences Publishers Inc, ISBN: 978-1-62100-027-3, New York.

- Lehmann S., Solassol J. & **Perrier V**. (2004) Cell culture models of TSEs. In "Methods and Tools in Biosciences and Medicine, Techniques in Prion Research". Lehmann and Grassi (eds), pp72-81, 2004 Birkhäuser Verlag AG.

- Perrier V. & Lehmann S. (2003). Anti-prion agents : From Congo red to quinacrine. In "*New Perspectives for Prion Therapeutics",* Sylvain Lehmann (eds), pp 45-54, 2003 Editions de Condé.

SEMINARS (Public or private laboratories)

- Huazhong University of Science and Technology, 10th July 2014, Wuhan, China. « Role of pesticides in neurodegenerative diseases » **Perrier V**. *invited* by Pr. Jianfeng Liu.

- I-STEM, AFM, Genopôle, Evry, 4octobre 2012. « Prions, pour le pire…et le meilleur ». **Perrier V.** *invited* by Dr. Brigitte Onteniente.

- Société Cell Vir, Biocitech, Technology park, 18th Janvier 2011, Paris. « Détection de la protéine pathologique du prion par les composés thiényls pyrimidiques ». Perrier V. *invited* by Dr. Richard Benarous

- Huazhong University of Science and Technology, 10th April 2009, Wuhan, China. « Which therapeutic advances after 20 years of mad cow diseases ? » **Perrier V**. *invited* by Pr. Jianfeng LIU.

- Société Thermofisher Scientific, 5th décembre 2008, Nantes. « Avancées thérapeutiques sur les maladies à prions après 20 ans de vache folle ». **Perrier V**. *invited* by Bertrand Tavernier, Directeur commercial France.

- Société LGC, (Laboratory Governmental Chemist), London, UK. 27th June 2008. Detection of the infectious prion protein in tissues and biological fluid. **Perrier V.** meeting organized by InsermTransfert

- BIOMERIEUX, Marcy l'Etoile, 13 juillet 2007. Détection de la protéine du prion dans les liquides biologiques. **Perrier V.** meeting organized by InsermTransfert

- Centre de Biochimie Structurale, 22 mars 2007, Montpellier. « Peut-on soigner les maladies à prions avec la protéine prion ? » **Perrier V.** *invited* by Dr. Emmanuel Margeat

- Institut de Génétique Humaine, 14 avril 2000, Montpellier. Identification de nouveaux inhibiteurs de la réplication des prions par une stratégie de drug-design**. Perrier V.** *invited* by Dr. Sylvain Lehmann

CONGRESS

1. Oral communication in congress and symposiums

Invited :

- Second Sino-French School of Oncology, 14-17 October 2014, Huazhong University of Science and Technology, Campus Biolake, Wuhan, China. « Pesticides and colorectal cancers : What role for PrP^C ? » **Perrier V.**

- XXVI^{éme} Congrès International du Groupe de Recherche sur la Maladie d'Alzheimer (GRAL), « Maladies Neuro-dégénératives : Nouveaux concepts », 25-26 janvier 2013, Marseille, France. Diagnosis and therapeutics of neurodegenerative diseases. **Perrier V.**

- Science Celebration Event on prion diseases and related disorders, 5-7 November 2012, Pollenzo, Italy. The dominant negative inhibition : from molecular mechanisms to therapy. **Perrier V.**

- Biovaria international congress, 15 May 2012, Munich, Germany. Thienyl pyrimidine and azine compounds to discriminate normal from prion-infected samples: application for diagnosis. **Perrier V.,** Imberdis T., Verdier J.-M. and Robitzer M.

- 2012 Sino-French meeting on Biological Science, 17-18 April 2012, Wuhan, China. « Diagnosis and therapeutics of neurodegenerative diseases ». **Perrier V.**

- 7ème congrès de la Société Française de Thérapie Cellulaire et Génique, 15-17 juin 2008, Presqu'île de Gien, France. La thérapie génique : stratégie effective pour le traitement tardif des maladies à prions. **Perrier V**. Biotherapy prize 2008 Thermo Fisher Scientific.

- VIème Congrès National de la Société Française de Microbiologie, 10-12 mai 2004, Bordeaux Lac. Session plénière dédiée aux maladies à prions. La protéine prion de mammifères : Du changement de conformation à la pathologie

Selected :

- ANR Bilan des programmes RIB 2006 et Emergence 2007, 14-15 Décembre 2010, Marseille, France. Détection de la protéine pathologique du prion par les dérivés thiényls pyrimidiques. **Perrier V.**

- Neuroprion meeting, 8-10 October 2008, Madrid, Spain. Therapeutic benefit from gene therapy in the curative treatment of prion diseases. Toupet K., Compan V., Crozet C., Mourton-Gilles C., Mestre-Francés N., Corbeau P., Verdier J.-M. & **Perrier V**.

- International Congress on Alzheimer's Diseases, 26-31 July 2008, Chicago, USA. Therapeutic benefit from gene therapy in the late treatment of prion diseases. **Verdier J.-M.**, Toupet K., Compan V., Crozet C., Mestre-Francés N., Corbeau P. & Perrier V.

- Journées de Génétique Humaine, 10-11 Décembre 2002, Mas de Saporta, Montpellier. Thérapeutique des maladies à prions. **Perrier V**.

- Fairchild Meeting, 20th January 2000, University of California, San Francisco. Mimicking dominant negative inhibition of prion replication through structure-based drug design. **Perrier V**., Wallace A., Kaneko K. & Prusiner S.B.

- Major Issues in Prion Research, XIIth Meeting, 18-20 November 1998, University of California, San Francisco. Identification of drugs to inhibit PrP^{Sc} formation. **Perrier V**., Wallace A., Kaneko K., Safar J., Prusiner S.B. & Cohen F.E.

- Fairchild Meeting, 8 January 1998, University of California, San Francisco. Identification of therapeutic agents to inhibit PrP^{Sc} formation : **Perrier V**., Wallace A., Kaneko K. & Prusiner S.B.

- XI^{e} Rencontres Interdisciplinaires de Biochimie, 15-19 Mai 1995, Saint Agnan, France.
Chélation du zinc chez les adényl kinases bactériennes. **Perrier V.** & Gilles A.M.

2. Posters

- Alzheimer Disease and Parkinson Disease meeting (AD/PD), 17-22 March 2015, Nice, France. Reduced circulating cholesterol levels in PLTP deficient mice increases survival time following prion infection. **Perrier V.**, Lafon P.-A., Cefis M., Imberdis T., Huetter E., Alvarez-Martinez M.-T., Arnaud J.-D., Desrumaux C.

- Prion 2012, 9-12 May 2012, Amsterdam, Netherlands. Centrifugation-based assay with thienyl azine compounds to discriminate normal from prion-infected samples. Imberdis T., Ayrolles-Torro A., Verdier J.-M., Robitzer M. & **Perrier V.**

- Symposium on Biology of Translational aspects of neurodegeneration, 12-14 March 2012, Venizia, Italy. Centrifugation-based assay with thienyl azine compounds to discriminate normal from prion-infected samples. Imberdis T., Ayrolles-Torro A., Verdier J.-M., Robitzer M. & **Perrier V.**

- Symposium on Biology of Translational aspects of neurodegeneration, 12-14 March 2012, Venizia, Italy. A thienyl azine compound exhibits a specific oligomeric activity on the pathologic PrP^{Sc} isoform and traps prion infectivity. Imberdis T., Ayrolles-Torro A., Torrent J., Verdier J.-M., Robitzer M. & **Perrier V.**

- Fondation IPSEN, colloque Médecine et Recherche, « Alzheimer, proteopathic seeds and neurodegenerative diseases », 27 February 2012, Paris.

- Prion 2011, New world, 16−19 May 2011, Montreal, Canada. Trapping prions with thienyl pyrimidine compounds. Imberdis T., Ayrolles−Torro A., Torrent J., Baskakov I., Poncet−Montange G., Lehman S., Pugniere M., Verdier J.-M., et **Perrier V.**

- Prion 2010, 8−11 September 2010, Salzburg, Austria. Dimerization of PrP^{Sc} by thienyl pyrimidine compounds trap prion infectivity. Ayrolles−Torro A., Torrent J., Baskakov I., Poncet−Montange G., Lehman S., Verdier J.-M., et **Perrier V.**

- Neuroprion meeting, 23-25 September 2009, Thessaloniki, Greece. Trapping prions in preamyloid forms by thienyl pyrimidine compounds. Ayrolles A.,Toupet K., Torrent J.,. Baskakov I., Poncet-Montange G., Lehmann S., Pugnière M., Verdier J.-M.et **Perrier V**.

- Neuroprion meeting, 8-10 October 2008, Madrid, Spain. Therapeutic benefit from gene therapy in the curative treatment of prion diseases. Toupet K., Compan V., Crozet C., Mourton-Gilles C., Mestre-Francés N., Corbeau P., Verdier J.-M.et **Perrier V**.

- Neuroprion meeting, 8-10 October 2008, Madrid, Spain. Pressure-induced aggregation pathways of prion protein. **El Moustaïne D.,** Perrier V., Lange R. & Torrent J.

- Neuroprion meeting, 8-10 October 2008, Madrid, Spain. Development of embryonic stem cell therapy for the treatment of prion diseases. Gabelle A., Hamela C., Relano-Gines A., Lin Y., De Vidi I., Mettling C., Corbeau P., Lehmann S., Perrier V. & **Crozet C**.

- 6ème Congrès de l'Ecole Doctorale Sciences Chimiques et Biologiques de Montpellier (cbs2) 5-7 mai 2008 . Elucidation des voies d'agrégation de la protéine prion recombinante par haute pression. **El Moustaïne D**., Perrier V., Lange R. & Torrent J. **Prix du Public 2008**

- Cambridge Healthtech Institute, Transmissible Spongiform Encephalopathies, 12th Annual meeting, 11-12 February 2008, Baltimore, MD, USA. Therapeutic effects of gene therapy in the late treatment of prion diseases. Toupet K., Compan V., Crozet C., Mestre-Francés N., Corbeau P., Verdier J.-M. & **Perrier V.**

- 8ème colloque de la Société des Neurosciences, 22-25 mai 2007, Montpellier, France. Therapeutic effects of gene therapy in the late treatment of prion diseases. Toupet K., Compan V., Gilles C., Crozet C., Mestre-Francés N., De Vidi I, Ibos F., Corbeau P., Verdier J.-M. & **Perrier V.**

- 8ème colloque de la Société des Neurosciences, 22-25 mai 2007, Montpellier, France. Evaluation of chemical compounds for the development of an early diagnostic test for prion diseases. Ayrolles A., Toupet K., Torrent J., Poncet-Montange G., Grégoire C., Mourton-Gilles C., Cobo S., Lehmann S., Verdier J.-M. & **Perrier V.**

- FENS, 8-12 July 2006, Vienna, Austria. Development of a gene and cell therapy strategy for the treatment of prion diseases. Crozet C., Lin Y.L., Corinus A., Mettling C., Corbeau P., Mourton-Gilles C., Lehmann S. & **Perrier V**.

- Neuroprion meeting, 2006, 4-6 October, Torino, Italy. Development of a gene and cell therapy strategy for the treatment of prion diseases. Crozet C., Lin Y.L., Corinus A., Mettling C., Corbeau P., Mourton-Gilles C., Lehmann S. & **Perrier V.**

- Neuroprion meeting, 19-21 October 2005, Düsseldorf, Germany. Inhibition of PrPSc replication by lentiviral gene transfer of dominant negative PrP mutants. Crozet C., Lin Y.L., Corinus A., Mettling C., Corbeau P., Mourton-Gilles C., Lehmann S. & **Perrier V.**

- 7ème colloque de la Société des Neurosciences, 17-20 mai 2005, Lille, France. Inhibition of PrP^{Sc} formation by lentiviral gene transfer of PrP containing dominant negative mutations. Crozet C., Lin Y.-L., Mettling C., Mourton-Gilles C., Corbeau P., Lehmann S. & **Perrier V.**

- 4th Forum of European Neuroscience, Lisbon, 10-14 July 2004. Inhibition of prion replication by lentiviral gene transfer of dominant negative PrPs mutants. Crozet C., Lin Y.L., Mettling C., Corbeau P., Lehmann S. & **Perrier V.**

- 1st International Conference of the Network of Excellence Neuroprion, Institut Pasteur, Paris, 24-28 May 2004. Inhibition of prion replication by lentiviral gene transfer of dominant negative PrPs mutants. Crozet C., Lin Y.L., Mettling C., Corbeau P., Lehmann S. & **Perrier V.**

- Keystone Symposia: Molecular aspects of prion diseases, Breckenridge, Colorado, 2-6 April 2003. Treatment of prion-infected cells by a combination of different anti-PrP antibodies accelerates prion clearance. **Perrier V.**, Solassol J., Crozet C., Frobert Y., Yee V., Gilles C., Grassi J. & Lehmann S.

- Réunion du programme de recherche 2001-2003 « Infections à prions », Ministère de la Recherche, Paris, 18 décembre 2002- Utilisation de virions exprimant des PrP dominantes négatives pour le traitement des maladies à prions. Crozet C., Mettling C., Lin Y.-L., Corbeau P., Lehmann S. & **Perrier V.**

- New perspectives for prion therapeutics, Paris, 1-3 December 2002. Treatment of scrapie-infected neuroblastoma cells by different anti-PrP antibodies accelerates prion clearance. **Perrier V.**, Solassol J., Crozet C., Frobert Y., Yee V., Grassi J. & Lehmann S.

- The New Prion Biology: Basic Science, Diagnosis and Therapy, Venizia, 12-13 April 2002.
Dominant negative inhibition in transgenic mice. **Perrier V.**, Kaneko K., Safar J., Tremblay P., Wallace A., Cohen F. E. & Prusiner S. B.

- Réunion de Biopathologie Comparée. Les Maladies Humaines et Animales à Prions, Val de Grâce, Ecole d'Application du Service de Santé des Armées, 18 octobre 2001

- International Symposium on Prion Diseases and Related Processes, Annecy, 12-15 November 2000. Mimicking dominant negative inhibition of prion replication trough structure-based drug design. **Perrier V**., Wallace A., Kaneko K., Safar J., Cohen F.E. & Prusiner S.B.

- American Academy of Neurology, San Diego, 29 April-6 may 2000. Mimicking dominant negative inhibition of prion replication trough structure-based drug design. **Perrier V**., Wallace A., Prusiner S.B. and Cohen F.E.

Posters from Ph.D.

- FEBS'96, 7-12 juillet 1996, Barcelone. Adenylate kinase from *Paracoccus denitrificans*, an iron and zinc binding protein which catalyses phosphorylation of AMP and reducytion of cytochrome c. **Perrier V.** & Gilles A.M.

Symposium Dynamics in Biological Functions of Adenylate Metabolism, 26-28 mars 1994, Ube, Yamaguchi, Japan. Zinc chelation by *Bacillus subtilis* adenylate kinase. Gilles A.M., **Perrier V.** & Glaser P.